
    
      The objective of the study was to evaluate maternal blood gas alterations among cases that
      use atosiban tocolytic agent and cases with terbutaline in in utero repair of
      myelomeningocele. It consists of a prospective, randomized, clinical, analytical study,
      covered for appraisers. It will include 28 patients, who will be divided into two groups that
      will receive two different tocolytics. The first group will receive terbutaline, and the
      second group will receive atosiban. The primary variable to be assessed will be maternal
      arterial pH at the end of surgery.
    
  